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Abstract 
Background: Genomic heterogeneity in human cancers complicates gene-centric personalized medicine. Malignant 
tumors often share a core group of pathways that are perturbed by diverse genetic mutations. Therefore, one possible 
solution to overcome the heterogeneity challenge is a shift from gene-centric to pathway-centric therapies. Pathway-
centric perspectives, which underscore the need to understand key pathways and their critical properties, could 
address the complexity of cancer heterogeneity better than gene-centric approaches to aid cancer drug discovery 
and therapy.
Methods: We used large-scale pharmacogenomic profiling data provided by the Cancer Genome Project of the Well-
come Trust Sanger Institute and the Cancer Cell Line Encyclopedia. In a systematic in silico investigation of ERK signal-
ling pathway components and topological structures determines their influences on pathway activity and targeted 
therapies. Mann–Whitney U test was used to identify gene alterations associated with drug sensitivity with p values 
and Benjamini–Hochberg correction for multiple hypotheses testing.
Results: The analysis demonstrated that genetic alterations were crucial to activation of effector pathway and sub-
sequent tumorigenesis, however drug sensitivity suffered from both drug effector and non-effector pathways, which 
were determined by not only underlying genomic alterations, but also interplay and topological relationship of com-
ponents in pathway, suggesting that the combinatorial targets of key nodes in perturbed pathways may yield better 
treatment outcome. Furthermore, we proposed a model to provide a more comprehensive insight and understand-
ing of pathway-centric cancer therapies.
Conclusions: Our study provides a holistic view of factors influencing drug sensitivity and sheds light on pathway-
centric cancer therapies.
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Background
The principle of personalized cancer therapy is to develop 
therapeutic strategies targeting specific genomic altera-
tions and/or perturbed pathways associated with specific 
cancers. Much of the ongoing effort has been directed 
at identifying individual biomarkers of effective thera-
pies and developing anticancer drugs targeting specific 
genomic alterations [1–4]. However, genomic heteroge-
neity in human cancers complicates gene-centric per-
sonalized medicine. Mutated genes vary widely across 
individual tumors. Indeed, the cancer genomic landscape 
proposed by Wood et  al. [5] describes tumor heteroge-
neity as mountains and hills representing frequently and 
infrequently mutated genes, respectively. Most of these 
altered genes are mutated only in a small percentage of 
tumors, and this heterogeneity has been a major obstacle 
to identify effective cancer therapies for many patients. 
Moreover, some altered proteins, such as RAS, are dif-
ficult to target therapeutically [6]. One possible solution 
Open Access
*Correspondence:  wanghaiyun@tongji.edu.cn 
†Haiyun Wang and Xiaoqi Zheng contributed equally to this work
1 School of Life Science and Technology, Tongji University, 
Shanghai 200092, China
Full list of author information is available at the end of the article
Page 2 of 9Wang et al. Clin Trans Med  (2015) 4:25 
to overcome the heterogeneity challenge is a shift from 
gene-centric to pathway-centric therapies.
Malignant tumors often share a core group of about 
a dozen perturbed pathways [7] that regulate specific 
aspects of oncogenesis and tumor metastasis and thereby 
affect cell fate determination, cell survival, and genome 
stability [8]. Pathway-oriented perspectives of cancer 
have important implications for discovering specialized 
therapies that broadly target key nodal points of altered 
pathways rather than targeting specific genetic altera-
tions associated with certain cancers [7–9].
However, before potential pathway-driven therapies 
can be utilized, it is necessary to understand the key 
pathways and their critical properties related to cancer. 
Two vital properties of pathways are components and 
structures. Pathway components, including genes and 
proteins, that are altered widely across individual tumors, 
but they often have overlapping functional consequences. 
For instance, 44% of squamous cell lung cancers harbor 
altered genes for squamous cell differentiation, includ-
ing overexpression and amplification of SOX2 and TP63; 
loss-of-function of NOTCH1, NOTCH2, and ASCL4; and 
focal deletions in FOXP1 [10]. Convergence of these dif-
ferent altered genes into specific cellular functions or 
pathways implies a possibility to target pathways, rather 
than individual mutated genes, for effective cancer ther-
apies. Therefore, mapping altered genes into pathways 
promises to simplify tumor mutation heterogeneity for 
cancer therapies. Pathway structures, with redundancy 
and feedback to maintain stable organismal functions, 
may also impact the therapeutic effect of target drugs. 
For instance, melanoma and colon cancer patients har-
boring the same BRAF (V600E) mutation respond differ-
ently to BRAF inhibitors because colon cancer cells but 
not melanoma cells gain feedback activation of EGFR 
and its signaling pathway [11]. Therefore, understand-
ing pathway structures and key nodal points targeted by 
therapeutic agents is fundamental for pathway-centric 
cancer therapies.
To develop effective pathway-centric therapies, it is 
necessary to reveal the impact of perturbed pathways and 
their topological structures on anticancer therapies. Two 
independent, large-scale pharmacogenomic datasets are 
available from the Cancer Genome Project (CGP) [12] 
and the Cancer Cell Line Encyclopedia (CCLE) [13], and 
currently they are under utilized to investigate the asso-
ciation between pathway properties and drug sensitiv-
ity. In this study, we analyzed high-throughput genomic 
information and pharmacological profiling of anticancer 
drugs across hundreds of cell lines using datasets pro-
vided by the CGP and CCLE. In particular, we focused on 
ERK signalling to systematically investigate the influence 
of gene alterations, and pathway topological structure on 
pathway activity and drug sensitivity. This represents a 
proof-of-principle study for modelling of pathway-cen-
tric cancer therapies.
Methods
Datasets
Gene expression, mutation, and drug sensitivity data 
were available from two independent large-scale pharma-
cogenomic studies, CGP (http://www.cancerrxgene.org) 
and CCLE (http://www.broadinstitute.org/ccle/). CGP 
included nearly 800 human tumour cell lines with full 
exon sequencing of 64 commonly mutated cancer genes, 
genome-wide analysis of copy number variation, analysis 
of seven commonly rearranged cancer genes, expression 
profiling of 14,500 genes, and pharmacological profiling 
for nearly 500 of 130 compounds. Human tumour cell 
lines cover the spectrum of common and rare types of 
adults and childhood cancers of epithelial, mesenchymal 
and haematopoietic origin. A range of 275–507 cell lines 
was screened per drug (mean = 368 cell lines per drug). 
Cells were treated with nine concentrations of drug for 
72  h before measuring cell number relative to controls 
[12]. The natural logarithm of the half maximal inhibitory 
concentration (IC50) represented drug sensitivity. CCLE 
included around ~500 human cancer cell lines profiled 
for mutations of >1,600 genes, copy number variation of 
~20,000 genes, expression profiling of ~20,000 genes, and 
pharmacological profiling of 24 compounds. These cell 
lines also cover multiple cancer types. Eight-point dose–
response curves were generated for 24 anticancer drugs 
using an automated compound-screening platform [13]. 
Drug response was represented by the area under the 
dose response curve, or activity area [14].
Data analysis
We classified cell lines into two groups based on the pres-
ence or absence of genomic alterations. Mann–Whitney 
U test was used to identify gene alterations associated 
with drug sensitivity with p values and Benjamini–Hoch-
berg correction for multiple hypotheses testing. Then, 
as a case study, we focused on drugs targeting the ERK 
signalling pathway (EGFR inhibitors, BRAF inhibitors, 
and MEK inhibitors) and oncogenes associated with ERK 
signalling, including EGFR, BRAF, KRAS, and NRAS. By 
integrating pathway structures, we unravelled the asso-
ciation between pathway structures and drug sensitivity. 
Our findings were further validated using an independ-
ent pharmacological study CCLE.
Results
For this study, we conducted the statistical analysis on the 
CGP dataset and validation on the CCLE dataset. CGP 
dataset consists of 64 commonly mutated cancer genes, 
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as well as their copy number variation, seven commonly 
rearranged cancer genes and drug sensitivity to 130 com-
pounds in nearly 800 cell lines. The results obtained from 
CGP were successively validated in the independent 
CCLE dataset, including around 500 human cancer cell 
lines profiled for mutations of >1,600 genes and pharma-
cological profiling of 24 compounds.
Genomic alterations affect pathway function and drug 
sensitivity
In CGP data, drug response was presented by the natural 
logarithm of the half maximal inhibitory concentration 
(IC50). To identify genes that influence drug sensitivity, 
we classified cell lines into two groups based on the pres-
ence or absence of genomic alterations. Mann–Whitney 
U test was used to identify gene alterations associated 
with drug sensitivity with p values and Benjamini–Hoch-
berg correction [15] for multiple hypotheses testing 
(Additional file 1: Table S1, adjusted p < 0.1).
One group of drugs that have shown promise in cancer 
therapy are the MEK inhibitors [16], including AZD6244, 
CI-1040, PD-0325901, and RDEA119, which inhibit ERK 
signalling by targeting MEK1/2 kinases. Based on the 
adjusted p value calculated by Mann–Whitney U test, 
we selected the top six genes mostly associated with drug 
sensitivity (adjusted p  <  0.1). Among them, cells with 
variants of BRAF, KRAS, NRAS and CDKN2A were sensi-
tive to MEK inhibitors, while cells with EWS-FLI1 gene 
translocations or RB1 mutations were resistant to them 
(Fig. 1).
BRAF, KRAS and NRAS are key oncogenes in the ERK 
signalling pathway, and activating mutations in BRAF, 
KRAS, and NRAS functionally overlap, inducing continu-
ous stimulation of the ERK pathway [17–19]. Since MEK 
inhibitors inhibit ERK signaling by targeting MEK1/2 
kinases, they may effectively treat tumors with KRAS, 
BRAF, or NRAS mutations [20]. This suggests that drugs 
are effective if they could successfully repress the ectopic 
activity of their targeting pathways. Meanwhile, cells har-
boring genomic aberrations in different pathways—for 
example, via EWS-FLI1 gene translocations or RB1 muta-
tions—were resistant to MEK inhibitors. That means 
drug non-effector pathways could also impact therapeu-
tic effects since they regulate specific aspects of oncogen-
esis and tumor metastasis as well.
Topological structures of drug effector pathways influence 
drug sensitivity
To investigate how topological pathway structures influ-
ence drug effects, we employed the ERK signalling path-
way with integration of mutation and drug targets for 
analysis (Fig.  2a). Since drugs targeting ERK signalling 
pathway, such as BRAF inhibitors and ERK inhibitors, are 
single-target compounds rather than multi-target ones, 
which benefits the association analysis between drug sen-
sitivity and genomic alterations. Moreover, CGP dataset 
includes a variety of drugs targeting ERK pathway. Drugs 
associated with this pathway were classified into three 
groups: EGFR inhibitors, BRAF inhibitors, and MEK 
inhibitors. The target genes of these inhibitors function 
upstream, midstream, and downstream, respectively, of 
the ERK pathway. Then, we focused on known oncogenes 
in the ERK pathway and used the Mann–Whitney U test 
to identify associations between pathway structure and 
drug sensitivity.
Mutations in EGFR, BRAF, KRAS, and NRAS can 
lead to acquired and increased ERK signalling activity 
(Fig.  2a). EGFR inhibitors, MEK inhibitors, and BRAF 
inhibitors can control the growth of cancer cells by abat-
ing extra pathway activity, so effects of these drugs par-
tially depend on their ability to control aberrant activity 
of the pathway due to activating oncogene mutations. In 
our analysis, cells with BRAF mutations were more sen-
sitive to BRAF inhibitors than cells with KRAS, NRAS, 
or EGFR mutations (Fig.  2b). KRAS, NRAS, and EGFR 
function upstream of BRAF in the signalling pathway. 
Signals could thus bypass BRAF through ARAF, CRAF, 
and MOS, which may exert similar functions as BRAF. 
Therefore, specific targeting of BRAF alone in cells with 
KRAS, NRAS, or EGFR mutations fails to inhibit ectopic 
activation of signals from upstream oncogenic mutations 
(Fig. 2a).
KRAS, NRAS, and BRAF mutations are associated 
with sensitivity to MEK inhibitors, but EGFR muta-
tions are not (Fig.  2c). MEK inhibitors target MEK1/2, 
which are pivotal to activating the downstream pathway. 
Although BRAF, KRAS, and NRAS are kinases upstream 
of MEK1/2, they pass signals down through MEK1/2 and 
do not function through other major signalling branches. 
Therefore, MEK inhibitors appear to effectively block 
aberrantly-activated signals from KRAS, NRAS, and 
BRAF.
Cells harboring EGFR, KRAS, NRAS, or BRAF muta-
tions displayed limited therapeutic responses to EGFR 
inhibitors compared with wildtype cells (Fig. 2d). EGFR 
is the cell-surface receptor upstream of ERK and PI3K 
signalling pathways, and BRAF, KRAS, and NRAS all 
function downstream of EGFR. Activating mutations in 
BRAF, KRAS and NRAS can confer constitutive acti-
vation of ERK signalling without stimulation of their 
upstream signalling, thus EGFR inhibitors are not ben-
eficial for cells with BRAF, KRAS, and NRAS mutations. 
A bit surprisingly, cells with EGFR mutation were not 
statistically more sensitive to EGFR inhibitors than cells 
without EGFR mutation for any inhibitors. Moreover, 
cells with EGFR mutation were not more sensitive to 
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BRAF and MEK1/2 inhibitors (Fig. 2b, c). Those results 
could be due to insufficient EGFR mutants in the CGP 
dataset [10/639 (1.56%)] or redundant pathways other 
than BRAF or MEK1/2 to transfer ectopic EGFR signals 
(e.g., PI3K). Our analysis suggests that there might exist 
the effective targeting nodes as potential pathway-cen-
tric therapies, which should locate in the downstream 
of a pathway and be a unique path for transferring 
signalling.
Validation with CCLE dataset
We used the independent CCLE dataset to confirm 
our findings. In CCLE data, the IC50 could not be esti-
mated in many cases, as drug concentration necessary 
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Fig. 1 Association between genomic alterations and drug sensitivity. Cells with the indicated mutations were analyzed for sensitivities to the 
structures of drugs AZD6244 (a), CI-1040 (b), PD-0325901 (c), or RDEA119 (d), measured as log (IC50). Each row in the heatmap represents a gene 
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to inhibit 50% of growth was not reached. Therefore, 
different from IC50 in CGP data, drug response in 
CCLE data was presented by the value of activity area 
and greater value means higher sensitivity (see “Meth-
ods”). In this dataset, BRAF, KRAS, and NRAS muta-
tions were still sensitive to MEK1/2 inhibitors (Fig. 3a, 
b).
Further, CCLE analysis from the view of topological 
structures also showed consistency with our previous 
CGP findings (Fig. 3c–e). Our analysis further confirmed 
that MEK inhibitors effectively inhibit ERK signalling by 
targeting MEK1/2 kinases and are applicable in the treat-
ment of tumors harboring KRAS, BRAF, and NRAS muta-
tions [20].
Model of pathway‑driven personalized medicine
Based on our analyses, we generated a conceptual model 
to delineate pathway-driven personalized medicine. In 
this model (Fig.  4), all pathways might be grouped into 
drug effector and non-effector pathways. We demon-
strated three types of representative cases (cases with 
good drug effect, cases without drug effect, and cases 
with partial drug effect) that delineate the association 
between activity change of perturbed pathways, includ-
ing drug effector and non-effector pathways, with drug 
sensitivity.
In the case with good drug effect, drug effector path-
ways are abnormally activated, which could be caused by 
two different mutant oncogenes in this pathway. Drug 
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non-effector pathways have normal signalling. In this 
case, drugs targeting effective targeting nodes of this per-
turbed pathway usually work well. The effective target-
ing nodes should be downstream and unique molecules 
in this pathway. By inhibiting these molecules, drugs are 
more likely to inhibit the activity of the whole pathway. 
For instance, MEK inhibitors completely inhibit ERK sig-
nalling by targeting MEK1/2 kinases, and are effective in 
treatment of tumors harboring KRAS, BRAF, or NRAS 
mutations. In two cases with no drug effect, the drug is 
not targeting the perturbed pathway or altered down-
stream genes gained ectopic activation independent of 
upstream stimulation, so treatment is ineffective. In two 
cases with partial drug effect, the first case simulates a 
tumor with multiple perturbed pathways. Single drugs 
targeting one pathway are often therapeutically ineffec-
tive because other perturbed pathways still provide cel-
lular growth or survival stimulation. In the second case 
with partial drug effect, the drug could not completely 
inhibit the activated pathway because its targets were not 
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unique molecules for activation of the downstream path-
way. In this case, the drug has little effect on cell growth.
Discussion
In this study, we systematically investigate ERK signal-
ling pathway components and topological structures 
that determine their influences on pathway activity and 
targeted therapies. A tumor is a dynamic entity that 
evolves by acquiring a series of mutations with advan-
tageous phenotypes, therefore a tumor in general has 
multiple perturbed pathways. Our analyses demonstrate 
that genomic alterations may affect multiple pathways, 
which could be classified as drug effector and non-
effector pathways by the way they target the two can-
cer hallmarks ‘sustaining proliferative signaling’ and 
‘evading growth suppressors’ [21]. Both the activity 
of drug effector pathways and drug non-effector path-
ways could affect therapeutic effects of target drugs. The 
researchers [22] have concluded that the idea that the 
presence of a specific mutation translates into sensitiv-
ity or resistance to a particular drug is likely too sim-
plistic, since it does not capture the complexity of the 
signalling pathways in an individual cancer. We finally 
generated a conceptual model to delineate pathway-
driven personalized medicine. In the third case of this 
model, pathway-centric personalized cancer therapies 
can represent combined therapies targeting different 
perturbed pathways.
Many pathway-centric studies were previously reported 
[23–27]. For example, Gene expression signature was 
identified to reflect the activation status of several onco-
genic pathways that were deregulated in tumours and 
clinically relevant associations with disease outcomes. 
They linked pathway deregulation with sensitivity to 
therapeutics to guide the use of targeted therapeutics 
[23]. Genes involved in oxidative stress response and 
squamous differentiation pathways were found to be fre-
quently altered by mutation or copy number alteration or 
up-/down- regulation in squamous cell lung cancer [27]. 
A limitation of these studies is that they relied on limited 
data or information between drugs and molecules. Our 
study utilizes two large-scale pharmacogenomic profiles 
and provides a different view for understanding pathway-
centric cancer therapies.
Our analysis showed that cells with EGFR mutation 
were not statistically more sensitive to EGFR inhibi-
tors than cells without EGFR mutation for any inhibi-
tors. In clinic EGFR inhibitors gefitinib and erlotinib are 
widely used in non-small-cell lung cancer patients with 
EGFR mutations for their dramatic efficacy [28–30]. 
However, clinical studies have shown that a small popu-
lation of patients with amplified, wild-type EGFR lung 
drug effector pathway
drug non-effector pathway
Good effect
No effect
Partial effect
altered gene
wild type gene
drug treatment
normal signaling
ectopic activated signaling
Fig. 4 Model of pathway-centric personalized medicine. Green and grey rectangles indicate drug effector and drug non-effector pathways, 
respectively; red and white circles represent individually altered and wildtype genes, respectively; normal and bold lines indicate normal and ectopic 
activated pathway signalling, respectively; and flash signs indicate drugs targeting specific molecules. One case with good drug effect, two cases 
with no drug effect, and two cases with partial drug effect are demonstrated.
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cancers also benefit from gefitinib or erlotinib [31, 32]. 
Our results could be due to insufficient EGFR mutants in 
the CGP dataset or atypical response of cell lines with-
out EGFR mutations. Moreover, some confounding fac-
tors, such as the cancer-type may complicate the drug 
sensitivity. In addition, the association between NRAS 
mutation and drug sensitivity are not totally statistically 
significant in all MEK inhibitors across the two datasets, 
which also could be due to insufficient NRAS mutants in 
the datasets. With the availability of more pharmocog-
enomic data, this statistical analysis will get more power.
Despite the encouraging results, our approach suffers 
from the following limitations. First, some confound-
ing factors, such as the cancer-type from which a cell 
line has been originated, or its genomic instability, may 
contribute to drug sensitivity. Stratification analysis or 
multivariate analysis could be preferred to determine the 
association between gene alterations and drug sensitiv-
ity. However, when focusing on the individual classes of 
mutations in the context of ERK signalling pathway, strat-
ification analysis or multivariate analysis could strongly 
reduce the population size for some test. Therefore, in 
this study univariate statistical test was used to deter-
mine gene alterations contributing to the increased level 
of resistance/sensitivity to a given drug. This analysis 
could over-estimate the significance of their association. 
Second, a recent study revealed significant discordance 
between CGP and CCLE datasets. These two studies used 
different experimental protocols. Differences include the 
pharmacological assay used, the range of drug concentra-
tions tested, and choice of an estimator for summarizing 
the drug sensitivity [33]. With the availability of more and 
better quality pharmocogenomic data, our approach will 
have more reliable findings.
Conclusions
We applied statistical methods to analyze two recently 
published pharmacogenomic datasets to investigate path-
way components and topological structures and their 
influences on targeted cancer therapies. The results show 
that activity of drug effector and non-effector pathways 
as determined by genomic alterations influence drug 
sensitivity, and key targeting nodes in specific pathways 
may yield better therapeutic predictions by pathway-
centric rather than gene-centric approaches. We propose 
a model to provide a more comprehensive understand-
ing of pathway-centric cancer therapies, which requires 
future in  vitro and in  vivo studies to validate the genes 
predicted to be affecting drug sensitivities. Our study 
demonstrates how pharmacogenomic profiling could be 
used to shed light on pathway-centric personalized can-
cer therapies.
Abbreviations
CGP: Cancer Genome Project in Wellcome Trust Sanger Institute; CCLE: The 
Cancer Cell Line Encyclopedia.
Authors’ contributions
HW and FZ conceived the study. HW and XZ designed and performed the 
statistical analyses. TF and YL discussed, revised and approved the manuscript. 
JW and XL participated in data collection and process. HW and FZ wrote 
the manuscript with help from XZ. All authors read and approved the final 
manuscript.
Author details
1 School of Life Science and Technology, Tongji University, Shanghai 200092, 
China. 2 Department of Mathematics, Shanghai Normal University, Shang-
hai 200234, China. 3 Department of Biostatistics and Computational Biology, 
Dana-Faber Cancer Institute and Harvard School of Public Health, Boston, 
MA 02215, USA. 4 Division of Molecular and Cellular Oncology, Department 
of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical 
School, Boston, MA 02215, USA. 5 Clinical Translational Research Center, 
Shanghai Pulmonary Hospital, School of Life Science and Technology, Tongji 
University, Shanghai 200092, China. 
Acknowledgements
This work was supported by National Natural Science Foundation of China 
(31100912 and 31329003). We thank X Shirley Liu for critically reading the 
manuscript.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 18 April 2015   Accepted: 1 July 2015
References
 1. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, 
Queirolo P et al (2013) MEK162 for patients with advanced melanoma 
harbouring NRAS or Val600 BRAF mutations: a non-randomised, 
open-label phase 2 study. Lancet Oncol 14(3):249–256. doi:10.1016/
S1470-2045(13)70024-X
 2. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H et al (2010) Clinical 
efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant 
melanoma. Nature 467(7315):596–599. doi:10.1038/nature09454
 3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J 
et al (2011) Improved survival with vemurafenib in melanoma with 
BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:10.1056/
NEJMoa1103782
 4. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas 
G et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the 
efficacy of cetuximab plus chemotherapy in chemotherapy-refractory 
metastatic colorectal cancer: a retrospective consortium analysis. Lancet 
Oncol 11(8):753–762. doi:10.1016/S1470-2045(10)70130-3
 5. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al (2007) The 
genomic landscapes of human breast and colorectal cancers. Science 
318(5853):1108–1113. doi:10.1126/science.1145720
 6. Downward J (2009) Cancer: a tumour gene’s fatal flaws. Nature 
462(7269):44–45. doi:10.1038/462044a
Additional file
Additional File 1: Table S1. Genes whose genomic alterations associ-
ated with drug sensitivity (Mann–Whitney U test, adjusted p < 0.1).
Page 9 of 9Wang et al. Clin Trans Med  (2015) 4:25 
 7. Jones D (2008) Pathways to cancer therapy. Nat Rev Drug Discov 
7(11):875–876. doi:10.1038/nrd2748
 8. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler 
KW (2013) Cancer genome landscapes. Science 339(6127):1546–1558. 
doi:10.1126/science.1235122
 9. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al (2008) 
Core signaling pathways in human pancreatic cancers revealed by 
global genomic analyses. Science 321(5897):1801–1806. doi:10.1126/
science.1164368
 10. Cancer Genome Atlas Research N (2012) Comprehensive genomic char-
acterization of squamous cell lung cancers. Nature 489(7417):519–525. 
doi:10.1038/nature11404
 11. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D 
et al (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibi-
tion through feedback activation of EGFR. Nature 483(7387):100–103. 
doi:10.1038/nature10868
 12. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al 
(2012) Systematic identification of genomic markers of drug sensitivity in 
cancer cells. Nature 483(7391):570–575. doi:10.1038/nature11005
 13. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim 
S et al (2012) The Cancer Cell Line Encyclopedia enables predictive 
modelling of anticancer drug sensitivity. Nature 483(7391):603–607. 
doi:10.1038/nature11003
 14. Wu R, Lin M (2008) Statistical and computational pharmacogenomics 
Chapman & Hall/CRC interdisciplinary statistics Chapman and Hall/CRC
 15. Benjamin Y, Hochberg Y (1995) Controlling the false discovery rate: a 
practical and powerful approach to multiple testing. J R Stat Soc Ser B 
(Methodological) 57:289–300
 16. Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond 
E (2014) MEK in cancer and cancer therapy. Pharmacol Ther 141(2):160–
171. doi:10.1016/j.pharmthera.2013.10.001
 17. Avruch J (2007) MAP kinase pathways: the first 20 years. Biochim Biophys 
Acta 1773(8):1150–1160. doi:10.1016/j.bbamcr.2006.11.006
 18. Ramos JW (2008) The regulation of extracellular signal-regulated kinase 
(ERK) in mammalian cells. Int J Biochem Cell B 40(12):2707–2719. 
doi:10.1016/J.Biocel.2008.04.009
 19. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A et al (2004) 
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and 
website. Br J Cancer 91(2):355–358. doi:10.1038/sj.bjc.6601894
 20. Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R et al (2013) 
Mechanism of MEK inhibition determines efficacy in mutant KRAS- 
versus BRAF-driven cancers. Nature 501(7466):232–236. doi:10.1038/
nature12441
 21. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. 
Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013
 22. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A (2012) Targeted 
therapies: how personal should we go? Nat Rev Clin Oncol 9(2):87–97. 
doi:10.1038/nrclinonc.2011.164
 23. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al (2006) Onco-
genic pathway signatures in human cancers as a guide to targeted 
therapies. Nature 439(7074):353–357. doi:10.1038/nature04296
 24. Segal E, Friedman N, Koller D, Regev A (2004) A module map show-
ing conditional activity of expression modules in cancer. Nat Genet 
36(10):1090–1098. doi:10.1038/ng1434
 25. Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M et al (2003) 
Gene expression phenotypic models that predict the activity of onco-
genic pathways. Nat Genet 34(2):226–230. doi:10.1038/ng1167
 26. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular 
signature of metastasis in primary solid tumors. Nat Genet 33(1):49–54. 
doi:10.1038/ng1060
 27. Cancer Genome Atlas Research Network (2012) Comprehensive genomic 
characterization of squamous cell lung cancers. Nature 489(7417):519–
525. doi:10.1038/nature11404
 28. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR 
mutations in lung cancer: correlation with clinical response to gefitinib 
therapy. Science 304(5676):1497–1500. doi:10.1126/science.1099314
 29. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan 
BW et al (2004) Activating mutations in the epidermal growth factor 
receptor underlying responsiveness of non-small-cell lung cancer to 
gefitinib. N Engl J Med 350(21):2129–2139. doi:10.1056/NEJMoa040938
 30. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al (2004) 
EGF receptor gene mutations are common in lung cancers from “never 
smokers” and are associated with sensitivity of tumors to gefitinib and 
erlotinib. Proc Natl Acad Sci USA 101(36):13306–13311. doi:10.1073/
pnas.0405220101
 31. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al 
(2005) Epidermal growth factor receptor gene and protein and gefitinib 
sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–655. 
doi:10.1093/jnci/dji112
 32. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J et al (2005) 
Erlotinib in lung cancer—molecular and clinical predictors of outcome. N 
Engl J Med 353(2):133–144. doi:10.1056/NEJMoa050736
 33. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ 
et al (2013) Inconsistency in large pharmacogenomic studies. Nature 
504(7480):389–393. doi:10.1038/nature12831
